Tryptamine Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on the development of an advanced and scalable intravenous-infused psilocin formulation, which can be used in conjunction with psychotherapy to address significant unmet medical needs. It is focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. It intends to accomplish this through the development of an IV infusion of psilocin (the active metabolite of psilocybin). Its lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. The Company is engaged in pursuing Phase II clinical trials using its psilocybin and psilocin-based drug products for chronic pain and eating disorders. The Company's pipeline products include TRP-8803 and TRP-8802.

• Revenue in AUD (TTM)1.21m
• Net income in AUD-4.32m
• Incorporated2013
• Employees--

• Location
  Tryptamine Therapeutics LtdC/o Bio101 Financial Advisory Pty LtdSuite 201, 697 Burke Road, CamberwellMELBOURNE 3124AustraliaAUS
• Phone+61 38419-0827
• Websitehttps://exopharm.com/